The prostate cancer risk stratification project: Database construction and risk stratification outcome analysis

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 1, 2014, Pages 60-69

  Rodrigues, George ^a   Lukka, Himu ^b   Warde, Padraig ^c   Brundage, Michael ^d   Souhami, Luis ^e   Crook, Juanita ^f   Cury, Fabio ^e   Catton, Charles ^c   Mok, Gary ^c   Martin, Andre Guy ^g   Vigneault, Eric ^g   Morris, Jim ^h   Warner, Andrew ^a   Maldonado, Sandra Gonzalez ^a   Pickles, Tom ^h  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d Cancer Centre of South Eastern Ontario   (Canada)

^e MONTREAL GENERAL HOSPITAL   (Canada)

^f KELOWNA GENERAL HOSPITAL   (Canada)

^g LAVAL UNIVERSITY   (Canada)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; DATA BASE; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROSTATE CANCER; QUALITY CONTROL; RADIATION DOSE FRACTIONATION; RADIATION ONCOLOGIST; RISK STRATIFICATION; TREATMENT OUTCOME; VERY ELDERLY;

AGED; BRACHYTHERAPY; CANADA; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RISK; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84893779094     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0007     Document Type: Article

References (31)

1. Kollmeier MA, Zelefsky MJ. How to select the optimal therapy for early-stage prostate cancer. Crit Rev Oncol Hematol 2012;83:225-234.
2. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomized phase 3 trial. Lancet 2011;378:2104-2111.
3. Pasquier D, Ballereau C. Adjuvant and salvage radiotherapy after prostatectomy for prostate cancer: a literature review. Int J Radiat Oncol Biol Phys 2008;72:972-979.
4. Viani GA, da Silva LG, Stefano EJ. High-dose conformal radiotherapy reduces prostate cancer-specific mortality: results of a meta-analysis. Int J Radiat Oncol Biol Phys 2012;83:e619-625.
5. Cuppone F, Bria E, Giannarelli D, et al. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. BMC Cancer 2010;10:675.
6. Peinemann F, Grouven U, Bartel C, et al. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur Urol 2011;60:881-893.
7. Ghilezan M. Role of high dose rate brachytherapy in the treatment of prostate cancer. Cancer Radiother 2012;16:418-422.
8. Vavassis P, Nguyen DH, Bahary JP, et al. Hypofractionated radiotherapy in prostate cancer. Expert Rev Anticancer Ther 2012;12:965-972.
9. Arcangeli S, Scorsetti M, Alongi F. Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. Crit Rev Oncol Hematol 2012;84:101-108.
10. Allen AM, Pawlicki T, Dong L, et al. An evidence based review of proton beam therapy: the report of ASTRO's emerging technology committee. Radiother Oncol 2012;103:8-11.
11. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
12. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106-2131.
13. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68-80.
14. Lukka H, Warde P, Pickles T, et al. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol 2001;8:1314-1322.
15. Graham J, Baker M, Macbeth F, et al. Diagnosis and treatment of prostate cancer: summary of NICE guidance. BMJ 2008;336:610-612.
16. Cooperberg MR, Lubeck DP, Mehta SS, et al. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003;170:S21-25.
17. Horwich A, Parker C, Bangma C, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21:v129-33.
18. Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate Cancer, Version 3.2012. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2012;10:1081-1087.
19. Mohler JL, Kantoff PW, Armstrong AJ, et al. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 1, 2014. Available at: NCCN.org. Accessed December 13, 2013.
20. Sutcliffe P, Hummel S, Simpson E, et al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technol Assess 2009;13:iii, xi-xiii 1-219.
21. Rodrigues G, Warde P, Pickles T, et al. Pre-treatment risk stratification of prostate cancer patients: A critical review. Can Urol Assoc J 2012;6:121-127.
22. Zaorsky NG, Li T, Devarajan K, Horwitz EM, et al. Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratification method. Cancer 2012;118:5535-5543.
23. Pickles T, Morris WJ, Kattan MW, et al. Comparative 5-year outcomes of brachytherapy and surgery for prostate cancer. Brachytherapy 2011;10:9-14.
24. Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-974.
25. Horwitz EM, Vicini FA, Ziaja EL, et al. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 1998;41:267-272.
26. Thompson A, Keyes M, Pickles T, et al. Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: can PSA kinetics distinguish PSA failures from PSA bounces? Int J Radiat Oncol Biol Phys 2010;78:415-421.
27. Beasley M, Williams SG, Pickles T, et al. Expanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapy. Radiat Oncol 2008;3:8.
28. Roach M 3rd, Weinberg V, Sandler H, et al. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score? Cancer 2007;109:213-220.
29. Lubeck DP, Litwin MS, Henning JM, et al. The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1996;48:773-777.
30. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220-241.
31. Zelefsky MJ, Kattan MW, Fearn P, et al. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology 2007;70:283-287.